<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04006041</url>
  </required_header>
  <id_info>
    <org_study_id>TORINEOEC</org_study_id>
    <nct_id>NCT04006041</nct_id>
  </id_info>
  <brief_title>Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer</brief_title>
  <official_title>A Phase II Trial of Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jianhua Fu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neoadjuvant chemoradiotherapy (CRT) followed by surgery has become the standard treatment
      option for locally advanced esophageal cancer (EC). However, only 20% to 40% of EC patients
      can achieve pathologic complete response (pCR) after neoadjuvant CRT with favorable
      prognosis. Immunotherapy targeting the PD-1/PD-L1 checkpoints has demonstrated promising
      activity in advanced EC. The aim of this study was to evaluate the efficacy and safety of the
      combination of toripalimab (an anti-PD-1 antibody) combined with neoadjuvant CRT in locally
      advanced esophageal squamous cell carcinoma (ESCC).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic complete response rate</measure>
    <time_frame>Three working days after surgery</time_frame>
    <description>The rate of pathologic complete response rate after neoadjuvant chemoradiotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>2-year overall survival</measure>
    <time_frame>From date of randomization until the date of death from any cause or the date of last follow-up, whichever came first, assessed up to 24 months</time_frame>
    <description>The 2-year overall survival of the whole group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year disease-free survival</measure>
    <time_frame>From date of surgery until the date of death from any cause or the date of first documented disease progression whichever came first, assessed up to 24 months.</time_frame>
    <description>The 2-year disease-free survival of the whole group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-related Adverse Events as Assessed by CTCAE v4.0</measure>
    <time_frame>From the enrollment to the date of surgery</time_frame>
    <description>The neoadjuvant treatment-related adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>Three working days after surgery</time_frame>
    <description>The R0 resection rate of esophagectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative complication rate</measure>
    <time_frame>From date of surgery to 30 days later</time_frame>
    <description>The perioperative complication rate of esophagectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative mortality</measure>
    <time_frame>From date of surgery to 30 days later</time_frame>
    <description>The perioperative mortality of esophagectomy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma by AJCC V8 Stage</condition>
  <condition>Resectable Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Toripalimab group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive standard fractionation radiation therapy (RT) scheme: 44Gy in 20 fractions over 4 weeks, concurrently with 4 cycles of paclitaxel/cisplatin (paclitaxel 50mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22 and 2 cycles of toripalimab 240 mg on days 1, 22. Esophagectomy is performed 6-8 weeks after CRT completion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toripalimab</intervention_name>
    <description>Patients received toripalimab 240 mg IVDRIP on days 1 and 22 during neoadjuvant radiotherapy.</description>
    <arm_group_label>Toripalimab group</arm_group_label>
    <other_name>JS-001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel/cisplatin</intervention_name>
    <description>Patients received 4 cycles of paclitaxel/cisplatin (paclitaxel 50mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22 during neoadjuvant radiotherapy.</description>
    <arm_group_label>Toripalimab group</arm_group_label>
    <other_name>TP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity-modulated radiotherapy</intervention_name>
    <description>All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 44 Gy in 20 fractions over 4 weeks.</description>
    <arm_group_label>Toripalimab group</arm_group_label>
    <other_name>IMRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Esophagectomy</intervention_name>
    <description>A transthoracic (Ivor-Lewis) esophagectomy is performed 6-8 weeks after CRT completion.</description>
    <arm_group_label>Toripalimab group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A histopathological diagnosis of resectable thoracic esophageal squamous cell
             carcinoma with a pre-treatment clinical stage of T1-4aN1-3M0 or T3-4aN0M0 according to
             the 8th edition of the UICC staging system;

          2. Patients who are anti-tumor treatment-naive;

          3. Estimated life expectancy &gt;6 months

          4. Aged 18 to 70 years old of either gender

          5. The function of important organs meets the following requirements: a. white blood cell
             count (WBC) ≥ 4.0×109/L, absolute neutrophil count (ANC) ≥ 1.5×109/L; b. platelets ≥
             100×109/L; c. hemoglobin ≥ 9g/dL; d. serum albumin ≥ 2.8g/dL; e. total bilirubin ≤
             1.5×ULN, ALT, AST and/or AKP ≤ 2.5×ULN; f. serum creatinine ≤ 1.5×ULN or creatinine
             clearance rate &gt;60 mL/min;

          6. PS score of 0-1;

          7. Ability to understand the study and sign informed consent.

        Exclusion Criteria:

          1. Patients who have been treated previously with anti-tumor therapy (including
             chemotherapy, radiotherapy, surgery, immunotherapy, etc.);

          2. Known or suspected allergy or hypersensitivity to monoclonal antibodies, any
             ingredients of Toripalimab, and the chemotherapeutic drugs paclitaxel or cisplatin;

          3. Patients who have a preexisting or coexisting bleeding disorder;

          4. Other uncontrollable inoperable patients;

          5. Female patients who are pregnant or lactating;

          6. Inability to provide informed consent due to psychological, familial, social and other
             factors;

          7. Presence of CTC grade ≥ 3 peripheral neuropathy;

          8. A history of malignancies other than esophageal cancer before enrollment, excluding
             non-melanoma skin cancer, in situ cervical cancer, or cured early prostate cancer

          9. A history of diabetes for more than 10 years and poorly controlled blood glucose
             levels;

         10. Patients who cannot tolerate chemoradiotherapy or surgery due to severe cardiac, lung,
             liver or kidney dysfunction, or hematopoietic disease or cachexia.

         11. Active autoimmune diseases, a history of autoimmune diseases (including but not
             limited to these diseases or syndromes, such as colitis, hepatitis, hyperthyroidism),
             a history of immunodeficiency (including a positive HIV test result), or other
             acquired or congenital immunodeficiency diseases, a history of organ transplantation
             or allogeneic bone marrow transplantation;

         12. A history of interstitial lung disease or non-infectious pneumonia;

         13. A history of active pulmonary tuberculosis infection within 1 year or a history of
             active pulmonary tuberculosis infection more than 1 year ago but without formal
             anti-tuberculosis treatment;

         14. Presence of active hepatitis B (HBV DNA ≥ 2000 IU/mL or 104 copies/mL), hepatitis C
             (positive for hepatitis C antibody, and HCV-RNA levels higher than the lower limit of
             the assay).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianhua Fu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mian Xi, MD</last_name>
    <phone>86-20-87343385</phone>
    <email>ximian@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hong Yang, MD</last_name>
    <phone>86-20-87343093</phone>
    <email>yanghong@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mian Xi, MD</last_name>
      <phone>86-20-87343385</phone>
      <email>ximian@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Jianhua Fu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, Mao W, Xiang J, Han Y, Chen Z, Yang H, Wang J, Pang Q, Zheng X, Yang H, Li T, Lordick F, D'Journo XB, Cerfolio RJ, Korst RJ, Novoa NM, Swanson SJ, Brunelli A, Ismail M, Fernando HC, Zhang X, Li Q, Wang G, Chen B, Mao T, Kong M, Guo X, Lin T, Liu M, Fu J; AME Thoracic Surgery Collaborative Group. Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial. J Clin Oncol. 2018 Sep 20;36(27):2796-2803. doi: 10.1200/JCO.2018.79.1483. Epub 2018 Aug 8.</citation>
    <PMID>30089078</PMID>
  </reference>
  <results_reference>
    <citation>Fu J, Wang F, Dong LH, Zhang J, Deng CL, Wang XL, Xie XY, Zhang J, Deng RX, Zhang LB, Wu H, Feng H, Chen B, Song HF. Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody. Acta Pharmacol Sin. 2017 May;38(5):710-718. doi: 10.1038/aps.2016.161. Epub 2017 Mar 20.</citation>
    <PMID>28317872</PMID>
  </results_reference>
  <results_reference>
    <citation>Tang B, Yan X, Sheng X, Si L, Cui C, Kong Y, Mao L, Lian B, Bai X, Wang X, Li S, Zhou L, Yu J, Dai J, Wang K, Hu J, Dong L, Song H, Wu H, Feng H, Yao S, Chi Z, Guo J. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. J Hematol Oncol. 2019 Jan 14;12(1):7. doi: 10.1186/s13045-018-0693-2.</citation>
    <PMID>30642373</PMID>
  </results_reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>June 26, 2019</study_first_submitted>
  <study_first_submitted_qc>June 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2019</study_first_posted>
  <last_update_submitted>December 22, 2019</last_update_submitted>
  <last_update_submitted_qc>December 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Jianhua Fu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Esophageal squamous cell carcinoma</keyword>
  <keyword>Neoadjuvant chemoradiotherapy</keyword>
  <keyword>Toripalimab</keyword>
  <keyword>Pathologic complete response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

